Abstract:Recently, we reported a new lead compound R/S-diphenyl[Nbenzyloxycarbonylamino(4-carbamoylphenyl) methyl] phosphonate as an inhibitor of prostate-specific antigen (PSA), for the control of prostate tumor progression.1 In this work, additional tripeptide derivatives of the lead compound were modeled using a similar approach. An incremental build method was utilized to improve computational efficiency of peptide docking. Molecular dynamics (MD) simulations were used to obtain trajectories of selected ligands and validate key interactions in the binding complexes . Additionally, the importance of the classic kallikrein loop (CKL) and its interaction with the extended substrate were highlighted in the MD analysis. This modeling study introduces tripeptide derivatives of aminoalkylphosphonates as stronger PSA inhibitors for prostate cancer treatment.

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition